keyword
MENU ▼
Read by QxMD icon Read
search

Ticagrelor

keyword
https://www.readbyqxmd.com/read/29452843/ticagrelor-versus-clopidogrel-in-east-asian-patients-with-acute-coronary-syndrome-systematic-review-and-meta-analysis
#1
Naoki Misumida, Shunsuke Aoi, Sun Moon Kim, Khaled M Ziada, Ahmed Abdel-Latif
BACKGROUND: Bleeding complications are associated with unfavorable outcomes in patients with acute coronary syndrome (ACS). Compared to Whites, several studies demonstrated a higher risk of bleeding in Asians who present with acute myocardial infarction. To date, the efficacy and safety of ticagrelor in East Asian population have not been well established. METHODS: We conducted a systematic review and meta-analysis of randomized controlled trials that compared ticagrelor and clopidogrel in East Asian patients with acute coronary syndrome (ACS)...
January 31, 2018: Cardiovascular Revascularization Medicine: Including Molecular Interventions
https://www.readbyqxmd.com/read/29452338/potential-benefits-of-prasugrel-and-ticagrelor-is-diabetics-are-not-substantiated-by-the-food-and-drug-administration-adverse-event-repository
#2
Victor L Serebruany, Moo Hyun Kim, Nikita Lomakin
No abstract text is available yet for this article.
February 14, 2018: European Heart Journal. Cardiovascular Pharmacotherapy
https://www.readbyqxmd.com/read/29451832/circulating-progenitor-cells-and-their-interaction-with-platelets-in-patients-with-an-acute-coronary-syndrome
#3
Prokopia T Tatsidou, Vasileios G Chantzichristos, Maria E Tsoumani, Sofia Sidiropoulou, Ioannis V Ntalas, John A Goudevenos, Konstantinos Stellos, Alexandros D Tselepis
CD34 + cells expressing KDR (CD34 + /KDR + ) represent a small proportion of circulating progenitor cells that have the capacity to interact with platelets and to differentiate into mature endothelial cells, thus contributing to vascular homeostasis and regeneration as well as to re-endothelialization. We investigated the levels of CD34 + and CD34 + /KDR + progenitor cells as well as their interaction with platelets in acute coronary syndrome (ACS) patients before the initiation (baseline) of their treatment with a P2Y 12 receptor antagonist, and at 5-days post-treatment (follow-up)...
February 16, 2018: Platelets
https://www.readbyqxmd.com/read/29447787/rationale-and-design-of-the-comparison-between-a-p2y12-inhibitor-monotherapy-versus-dual-antiplatelet-therapy-in-patients-undergoing-implantation-of-coronary-drug-eluting-stents-smart-choice-a-prospective-multicenter-randomized-trial
#4
Young Bin Song, Seok Kyu Oh, Ju-Hyeon Oh, Eul-Soon Im, Deok-Kyu Cho, Byung Ryul Cho, Jong-Young Lee, Joo Myung Lee, Taek Kyu Park, Jeong Hoon Yang, Jin-Ho Choi, Seung-Hyuck Choi, Sang Hoon Lee, Hyeon-Cheol Gwon, Joo-Yong Hahn
BACKGROUND AND RATIONALE: Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor reduces thrombotic events in patients undergoing percutaneous coronary intervention (PCI), but these benefits come at the expense of increased risk of bleeding when compared with aspirin monotherapy. It is unclear whether P2Y12 inhibitor monotherapy might maintain anti-ischemic efficacy while reducing the bleeding risk compared with DAPT after implantation of the current generation of drug-eluting stents (DES)...
March 2018: American Heart Journal
https://www.readbyqxmd.com/read/29443445/aspirin-withdrawal-in-patients-treated-with-ticagrelor-presenting-with-non-st-elevation-myocardial-infarction
#5
Roy Beigel, Israel Mazin, Edward Koifman, Michael Shechter, Hanna Pres, Nir Shlomo, Nurit Rosenberg, Elad Asher, Shlomi Matetzky
BACKGROUND: Recent studies have shown that the thromboxaneA 2 -dependent pathway is dependent upon the adenosine diphosphate (ADP)-P2Y 12 pathway and that strong P2Y 12 receptor blockade alone causes inhibition of platelet aggregation that is minimally enhanced by aspirin. Data from the PLATO trial suggested that among ticagrelor-treated patients, high compared with low dose (<100mg\day) aspirin is associated with increased risk for ischemic events. OBJECTIVES: In the current prospective, randomized, placebo-controlled, double-blind, cross-over study, we sought to evaluate the impact of aspirin withdrawal on platelet reactivity in acute coronary syndrome (ACS) patients treated with a potent P2Y 12 blocker...
February 14, 2018: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/29443375/ischaemic-events-and-stent-thrombosis-following-planned-discontinuation-of-study-treatment-with-ticagrelor-or-clopidogrel-in-the-plato-study
#6
Robert F Storey, Diego Ardissino, Luigi Vignali, Richard Cairns, Richard C Becker, Christopher P Cannon, Kenneth W Mahaffey, Anders Himmelmann, Hugo A Katus, Stefan K James, Lars Wallentin
No abstract text is available yet for this article.
February 2018: Thrombosis and Haemostasis
https://www.readbyqxmd.com/read/29442148/population-pharmacokinetics-and-pharmacodynamics-of-ticagrelor-and-ar-c124910xx-in-chinese-healthy-male-subjects
#7
Shuaibing Liu, Ling Xue, Xiangfen Shi, Zhiyong Sun, Zhenfeng Zhu, Xiaojian Zhang, Xin Tian
BACKGROUND: Ticagrelor, the first reversible P2Y 12 receptor antagonist, exhibits faster onset and offset of antiplatelet effects and more consistent platelet inhibition than clopidogrel in both healthy subjects and patients with stable coronary artery disease. OBJECTIVE: The objectives of this study were to establish a population pharmacokinetics (PK) and pharmacodynamics (PD) model of ticagrelor and to provide a theoretical basis for the optimization of ticagrelor treatment in clinic...
February 13, 2018: European Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/29437885/association-of-different-antiplatelet-therapies-with-mortality-after-primary-percutaneous-coronary-intervention
#8
Ivan Olier, Alex Sirker, David J R Hildick-Smith, Tim Kinnaird, Peter Ludman, Mark A de Belder, Andreas Baumbach, Jonathan Byrne, Muhammad Rashid, Nick Curzen, Mamas A Mamas
OBJECTIVES: Prasugrel and ticagrelor both reduce ischaemic endpoints in high-risk acute coronary syndromes, compared with clopidogrel. However, comparative outcomes of these two newer drugs in the context of primary percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI) remains unclear. We sought to examine this question using the British Cardiovascular Interventional Society national database in patients undergoing primary PCI for STEMI. METHODS: Data from January 2007 to December 2014 were used to compare use of P2Y12 antiplatelet drugs in primary PCI in >89 000 patients...
February 2, 2018: Heart: Official Journal of the British Cardiac Society
https://www.readbyqxmd.com/read/29421015/duration-of-ischemia-and-treatment-effects-of-pre-versus-in-hospital-ticagrelor-in-patients-with-st-segment-elevation-myocardial-infarction-insights-from-the-atlantic-study
#9
Akshay Bagai, Shaun G Goodman, Warren J Cantor, Eric Vicaut, Leonardo Bolognese, Angel Cequier, Mohamed Chettibi, Christopher J Hammett, Kurt Huber, Magnus Janzon, Frédéric Lapostolle, Jens Flensted Lassen, Béla Merkely, Robert F Storey, Jurriën M Ten Berg, Uwe Zeymer, Abdourahmane Diallo, Christian W Hamm, Anne Tsatsaris, Jad El Khoury, Arnoud W Van't Hof, Gilles Montalescot
BACKGROUND: Among patients with STEMI in the ATLANTIC study, pre-hospital administration of ticagrelor improved post-PCI ST-segment resolution and 30-day stent thrombosis. We investigated whether this clinical benefit with pre-hospital ticagrelor differs by ischemic duration. METHODS: In a post hoc analysis we compared absence of ST-segment resolution post-PCI and stent thrombosis at 30 days between randomized treatment groups (pre- versus in-hospital ticagrelor) stratified by symptom onset to first medical contact (FMC) duration [≤1 hour (n = 773), >1 to ≤3 hours (n = 772), and >3 hours (n = 311)], examining the interaction between randomized treatment strategy and duration of symptom onset to FMC for each outcome...
February 2018: American Heart Journal
https://www.readbyqxmd.com/read/29421001/thrombus-aspiration-and-prehospital-ticagrelor-administration-in-st-elevation-myocardial-infarction-findings-from-the-atlantic-trial
#10
Sinem Kilic, Enrico Fabris, Arnoud W J Van't Hof, Christian W Hamm, Frédéric Lapostolle, Jens Flensted Lassen, Anne Tsatsaris, Abdourahmane Diallo, Eric Vicaut, Gilles Montalescot
BACKGROUND: The potential interactions between prehospital (pre-H) ticagrelor administration and thrombus aspiration (TA) in patients with ST-elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (PCI) have never been studied. Therefore, we evaluated the potential benefit of TA and pre-H ticagrelor treatment in patients enrolled in the ATLANTIC trial (NCT01347580). METHODS: This analysis included 1,630 patients who underwent primary PCI...
February 2018: American Heart Journal
https://www.readbyqxmd.com/read/29415954/antiplatelet-therapy-in-acs-patients-comparing-appropriate-p2y12-inhibition-by-clopidogrel-to-the-use-of-new-p2y12-inhibitors
#11
Jessica Ristorto, Nathan Messas, Benjamin Marchandot, Marion Kibler, Sébastien Hess, Nicolas Meyer, Michael Schaeffer, Nicolas Tuzin, Patrick Ohlmann, Laurence Jesel, Olivier Morel
AIM: In percutaneous coronary intervention (PCI)-treated acute coronary syndrome (ACS) patients on clopidogrel therapy, high on-treatment platelet adenosine diphosphate (ADP) reactivity was observed in numerous studies, with significant increases in non-fatal myocardial infarction, definite/probable stent thrombosis, or cardiovascular mortality. Compared to clopidogrel, prasugrel and ticagrelor provide more potent platelet inhibition. Whether new P2Y12 inhibitors reduce thrombotic events in a similar manner compared to the rate observed with appropriate P2Y12 inhibition by clopidogrel must still be determined...
February 8, 2018: Journal of Atherosclerosis and Thrombosis
https://www.readbyqxmd.com/read/29412111/efficacy-of-p2y12-receptor-blockers-after-myocardial-infarction-and-genetic-variability-of-their-metabolic-pathways
#12
Jan Machal, Ota Hlinomaz
BACKGROUND: Various antiplatelet drugs are used following acute coronary syndromes (ACS). Of them, adenosine diphosphate receptor P2Y12 inhibitors clopidogrel, prasugrel and ticagrelor are currently used for post-ACS long-term treatment. Although they act on the same receptor, they differ in pharmacodynamics and pharmacokinetics. Several enzymes and transporters involved in the metabolism of P2Y12 inhibitors show genetic variability with functional impact. This includes P-glycoprotein, carboxylesterase 1 and, most notably, CYP2C19 that is important in clopidogrel activation...
February 5, 2018: Current Vascular Pharmacology
https://www.readbyqxmd.com/read/29406854/impact-of-ticagrelor-in-patients-with-prior%C3%A2-mi-and-mvd-for-reducing-cardiovascular-events
#13
EDITORIAL
Michael S Lee, Michael T Tanoue
No abstract text is available yet for this article.
February 6, 2018: Journal of the American College of Cardiology
https://www.readbyqxmd.com/read/29406853/ticagrelor-for-secondary-prevention-of-atherothrombotic-events-in-patients-with%C3%A2-multivessel-coronary-disease
#14
Sameer Bansilal, Marc P Bonaca, Jan H Cornel, Robert F Storey, Deepak L Bhatt, Ph Gabriel Steg, Kyungah Im, Sabina A Murphy, Dominick J Angiolillo, Robert G Kiss, Alexander N Parkhomenko, Jose Lopez-Sendon, Daniel Isaza, Assen Goudev, Frederic Kontny, Peter Held, Eva C Jensen, Eugene Braunwald, Marc S Sabatine, A J Oude Ophuis
BACKGROUND: Patients with prior myocardial infarction (MI) and multivessel coronary disease (MVD) are at high risk for recurrent coronary events. OBJECTIVES: The authors investigated the efficacy and safety of ticagrelor versus placebo in patients with MVD in the PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis In Myocardial Infarction 54) trial. METHODS: Patients with a history of MI 1 to 3 years before inclusion in the PEGASUS-TIMI 54 trial were stratified in a pre-specified analysis based on the presence of MVD...
February 6, 2018: Journal of the American College of Cardiology
https://www.readbyqxmd.com/read/29405601/the-promise-of-effective-p2y12-platelet-receptor-pretreatment-not-crushed-yet
#15
EDITORIAL
Arka Chatterjee, William B Hillegass
Pre-treatment with intact oral clopidogrel and prasugrel tablets in a representative observational study is not associated with altered ischemic or bleeding outcomes in acute coronary syndrome (ACS) patients. Limited by cost, cangrelor, a rapidly acting intravenous P2Y12 platelet receptor inhibitor, achieved meaningful reductions in major adverse cardiovascular events (MACE) and stent thrombosis (ST) compared to oral clopidogrel pretreatment. Crushed prasugrel and ticagrelor (CP&T) administered orally achieve accepted thresholds of therapeutic platelet inhibition in one hour in approximately 2/3rds of patients compared to 1/3rd with intact oral tablets...
February 1, 2018: Catheterization and Cardiovascular Interventions
https://www.readbyqxmd.com/read/29398917/ticagrelor-toward-more-efficient-platelet-inhibition-and-beyond
#16
REVIEW
Michał J Kubisa, Mateusz P Jezewski, Aleksandra Gasecka, Jolanta M Siller-Matula, Marek Postuła
Novel antiplatelet drugs, including ticagrelor, are being successively introduced into the therapy of atherothrombotic conditions due to their superiority over a standard combination of clopidogrel with acetylsalicylic acid in patients with acute coronary syndromes (ACS). A P2Y12 receptor antagonist, ticagrelor, is unique among antiplatelet drugs, because ticagrelor inhibits the platelet P2Y12 receptor in a reversible manner, and because it demonstrates a wide palette of advantageous pleiotropic effects associated with the increased concentration of adenosine...
2018: Therapeutics and Clinical Risk Management
https://www.readbyqxmd.com/read/29393120/prevalence-of-chronic-kidney-disease-thrombotic-cardiovascular-events-and-use-of-oral-p2y12-inhibitors-among-veterans
#17
Manisha Singh, Deepa Raghavan, James S Williams, Bradley C Martin, Teresa J Hudson, Richard R Owen, Nishank Jain
BACKGROUND: Contemporary prevalence of chronic kidney disease (CKD) and thrombotic cardiovascular (CV) events remains unclear in Veterans enrolled in the Veterans Affairs Health Care System (VA) care. Although oral P2Y12 inhibitors (P2Y12i) are increasingly being prescribed to this patient population, the overall prescription trend for P2Y12i remains unclear. METHODS: Using national VA corporate warehouse data, we used International Classification of Diseases-9 codes to identify Veterans with CKD, dialysis-dependent CKD, and CV events...
February 1, 2018: American Journal of Nephrology
https://www.readbyqxmd.com/read/29390379/successful-coronary-stenting-in-a-patient-with-factor-v-deficiency-in-the-absence-of-fresh-frozen-plasma-transfusion-case-report
#18
Seongil Choi, MooKon Song
RATIONALE: Drug-eluting stent (DES) implantation in a patient with factor V deficiency (F5D) is very complex. No antithrombotic therapy study has been reported for F5D patients who undergo a coronary stenting procedure. PATIENT CONCERNS: A 73-year-old woman presented with chest discomfort and exertional dyspnea. Coronary stenting was performed successfully using DES stents. DIAGNOSES: The D-dimer, prothrombin time, and partial thromboplastin time prolongation persisted from admission until 24 hours after coronary stenting...
December 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29390064/fibrin-clot-properties-independently-predict-adverse-clinical-outcome-following-acute-coronary-syndrome-a-plato-substudy
#19
Wael Sumaya, Lars Wallentin, Stefan K James, Agneta Siegbahn, Katja Gabrysch, Maria Bertilsson, Anders Himmelmann, Ramzi A Ajjan, Robert F Storey
Aims: To determine whether fibrin clot properties are associated with clinical outcomes following acute coronary syndrome (ACS). Methods and results: Plasma samples were collected at hospital discharge from 4354 ACS patients randomized to clopidogrel or ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial. A validated turbidimetric assay was employed to study plasma clot lysis time and maximum turbidity (a measure of clot density). One-year rates of cardiovascular (CV) death, spontaneous myocardial infarction (MI) and PLATO-defined major bleeding events were assessed after sample collection...
January 29, 2018: European Heart Journal
https://www.readbyqxmd.com/read/29389336/bleeding-frequency-of-patients-taking-ticagrelor-aspirin-clopidogrel-and-dual-antiplatelet-therapy-after-tooth-extraction-and-minor-oral-surgery
#20
Ozge Doganay, Belir Atalay, Erhan Karadag, Ugur Aga, Mehmet Tugrul
BACKGROUND: Perioperative bleeding complications of ticagrelor, a newer oral antiplatelet, has not been studied in dentistry. Studies about bleeding status after oral surgical procedures in patients receiving continued antiplatelet therapy are also limited. We investigated the effects of continuing aspirin, clopidogrel, ticagrelor, or dual antiplatelet therapy on the frequency of bleeding events in patients undergoing tooth extractions or minor oral surgery. METHODS: In this retrospective study, patient demographic characteristics, medical history, type of antiplatelet therapy, dental procedures, and perioperative bleeding associated with tooth extraction or other minor oral surgical procedures were obtained from the dental records of 222 patients...
February 2018: Journal of the American Dental Association
keyword
keyword
3908
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"